GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aravive Inc (NAS:ARAV) » Definitions » Earnings Yield %

Aravive (Aravive) Earnings Yield % : N/A% (As of Apr. 27, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Aravive Earnings Yield %?

The earnings yield is an indication of how much return shareholders' investment in the company earned over the past 12 months. The higher the earnings yield is, the better.

As of today (2024-04-27), the stock price of Aravive is $0.0401. Aravive's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $-0.96. Therefore, Aravive's earnings yield of today is N/A%.

The earnings yield does not consider the growth of the business. A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Aravive's Forward Rate of Return (Yacktman) % for the quarter that ended in Sep. 2023 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


Aravive Earnings Yield % Calculation

Earnings yield is the reciprocal of the P/E Ratio.

Aravive's Earnings Yield for today is calculated as

Earnings Yield=Earnings per Share (Diluted) (TTM)/Share Price
=-0.960/0.0401
=N/A %

Aravive's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.960 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Earnings Yield=Net Income /Market Cap

The earnings in the calculation is the Trailing Twelve Months earnings.


Aravive  (NAS:ARAV) Earnings Yield % Explanation

If the P/E ratio is an indication of how many years it takes for the company to earn back the stock price shareholders pay to buy the shares, the earnings yield is an indication of how much return shareholders' investment in the company earned over the past 12 months. The higher the earnings yield is, the better.

If a company loses money, the earnings yield is negative. This gives a more straightforward indication that the company is losing money. This is an advantage of using earnings yield instead of the P/E ratio in valuation. For valuation purposes, the P/B Ratio and the P/S Ratio should be used for companies that are losing money.

Like the P/E ratio, the earnings yield can be used to compare investments in different industries. It can even be used to compare the attractiveness of different asset classes such as bonds and cash. Of course, the earnings yield should not be the only factor in deciding which asset classes to invest.

Also similar to the P/E ratio, the earnings yield does not consider the growth of the business. A growing company with the same earnings yield should be more attractive than a company that has the same earnings yield but does not grow.

A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %.

Be Aware

Just like the P/E Ratio, non-recurring items such as selling part of the business, selling a previous investment, etc., can affect earnings yield dramatically. The earning yield is also a poor indication for cyclical companies. When a cyclical stock has a high earnings yield it is usually at the peak of its cycle.


Aravive Earnings Yield % Related Terms

Thank you for viewing the detailed overview of Aravive's Earnings Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Aravive (Aravive) Business Description

Traded in Other Exchanges
Address
3730 Kirby Drive, River Oaks Tower, Suite 1200, Houston, TX, USA, 77098
Aravive Inc is a clinical-stage biopharmaceutical company. It focuses on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. The company pipeline product Batiraxcept (formerly AVB-500) which is an ultra-high affinity decoy protein that binds to GAS6 and thereby prevents AXL signaling to inhibit metastasis and tumor growth and restore sensitivity to anti-cancer agents. Batiraxcept is currently being evaluated in multiple clinical trials.
Executives
Maria Carolina Petrini officer: Chief Commercial Officer RIVER OAKS TOWER, 3730 KIRBY DRIVE, SUITE 1200, HOUSTON TX 77098
Robert B. Geller officer: Chief Medical Officer RIVER OAKS TOWER, 3730 KIRBY DRIVE, SUITE 1200, HOUSTON TX 77098
Rudy Howard officer: Chief Financial Officer 322 WINDCHASE LANE, WILMINGTON NC 28409
Leonard Scott Dove officer: Chief Operating Officer RIVER OAKS TOWER, 3730 KIRBY DRIVE, SUITE 1200, HOUSTON TX 77098
Amato Giaccia director, 10 percent owner C/O VERSARTIS, INC., 1020 MARSH ROAD, MENLO PARK CA 94025
Gail Frances Mcintyre officer: Chief Scientific Officer C/O FURIEX PHARMACEUTICALS, INC., 3900 PARAMOUNT PARKWAY, SUITE 150, MORRISVILLE NC 27560
John Hohneker director C/O DIMENSION THERAPEUTICS, INC., 840 MEMORIAL DRIVE 4TH FLOOR, CAMBRIDGE MA 02139
Sigurd Kirk director 225 SUMMIT AVENUE, MONTVALE NJ 07645
Peter Tai-ching Ho director C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Vinay Shah officer: Chief Financial Officer C/O VERSARTIS, INC., 1020 MARSH ROAD, MENLO PARK CA 94025
Reshma Rangwala officer: Chief Medical Officer RIVER OAKS TOWER, 3730 KIRBY DRIVE, SUITE 1200, HOUSTON TX 77098
Michael W Rogers director C/O KERYX BIOPHARMACEUTICALS INC, ONE MARINA PARK DRIVE, BOSTON MA 02210
Eshelman Ventures, Llc director 319 N. 3RD STREET, SUITE 301, WILMINGTON NC 28401
Fredric N Eshelman director PPD INC, 929 NORTH FRONT STREET, WILMINGTON NC 28401
Rekha Hemrajani director, officer: President and CEO 3928 POINT EDEN WAY, HAYWARD CA 94545

Aravive (Aravive) Headlines